We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Newly Driver Mutations Discovered for Medulloblastoma

By LabMedica International staff writers
Posted on 31 Jul 2017
Print article
Image: Co-first author Paul Northcott, Ph.D., an assistant member of the St. Jude Department of Developmental Neurobiology and author Xin Zhou, PhD, senior bioinformatics research scientist (Photo courtesy of Seth Dixon / St. Jude Children\'s Research Hospital).
Image: Co-first author Paul Northcott, Ph.D., an assistant member of the St. Jude Department of Developmental Neurobiology and author Xin Zhou, PhD, senior bioinformatics research scientist (Photo courtesy of Seth Dixon / St. Jude Children\'s Research Hospital).
An international consortium has completed a landmark genomics study of medulloblastoma, the most common pediatric brain tumor, revealing much information about subtypes and laying a foundation to expand precision medicine. The most comprehensive analysis yet of medulloblastoma identified genomic changes responsible for over 75% of the many tumors examined; as well as two new suspected cancer genes found exclusively in the least understood disease subgroups.

The study was co-led by researchers at St. Jude Children’s Hospital (Memphis, TN, USA), German Cancer Research Center (Heidelberg, Germany), and Hospital for Sick Children (Toronto, ON, Canada). Whole genome or whole exome sequencing was done on tumor and normal tissue collected from 491 medulloblastoma patients at diagnosis. The team also analyzed DNA methylation and complementary epigenetic data from 1,256 medulloblastoma patients and gene expression data from 392 tumors. The ProteinPaint program was used to help visualize genome data.

“Layering genetic, epigenetic, and transcriptional data, combined with better analytic tools, led to discoveries that would have previously been missed in this highly complex and variable cancer,” said co-first author Paul Northcott, PhD, of St. Jude. Co-author Amar Gajjar, MD, of St. Jude, added: “Using advanced genomic techniques to gain insight into what genetic abnormalities cause medulloblastoma is essential for developing relevant models.”

“Our goal is to understand each patient’s tumor at the molecular level in order to better tailor treatment,” said Dr. Northcott, “This study provides a rich resource for neuro-oncology researchers and clinicians.” It can aid efforts to develop medicines designed to increase survival while reducing treatment-related side effects.

Medulloblastoma is the most common malignant pediatric brain tumor. There are four principal subgroups: WNT, Sonic Hedgehog (SHH), Group 3, and Group 4. The subgroups are driven by different genetic alterations, begin in different cells, and often exhibit different clinical outcomes. About 95% of patients in the WNT subgroup become long-term survivors compared to about 50% for Group 3 patients. There are currently no targeted therapies for Group 3 and Group 4 tumors, which account for over 65% of medulloblastoma cases.

The discoveries include identification of two new suspected oncogenes: KBTBD4 and PRDM6. The genes were found only in Group 3 and Group 4 medulloblastoma and had not previously been associated with any cancer. KBTBD4 was the most frequently mutated gene in those subgroups, involving insertion of one or two amino acids in the same mutation hot spot. The KBTBD4 protein is predicted to function in conjunction with ubiquitin ligase enzymes, but research is underway to better understand how the normal and mutant proteins function.

PRDM6 is an epigenetic regulator of gene activity whose own expression was dramatically increased in 17% of the Group 4 medulloblastoma tumors. If PRDM6 is confirmed to be an oncogene, researchers hope it will lead to development of the first laboratory model of Group 4 medulloblastoma. Such models play a pivotal role in clinical advances.

Overall, the integrated genomic analysis led to identification of altered genes and cellular pathways responsible for over 75% of patients’ tumors. The data also revealed additional complexity within different medulloblastoma subgroups, particularly Group 3 and Group 4. Researchers can access processed study data at no cost through the St. Jude PeCan data portal, the R2: Genomics Analysis and Visualization Platform and the PedcBioPortal for Cancer Genomics.

“The more refined classification of medulloblastoma offered in this study opens avenues for improved risk-stratification of patients and more tailored therapies that target the genomic alterations driving their disease,” said Dr. Gajjar.

The study, by Northcott PA et al, was published July 19, 2017, in the journal Nature.

Related Links:
St. Jude Children’s Hospital
German Cancer Research Center
Hospital for Sick Children


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.